Download Exploiting Vulnerabilities - American Association for Cancer Research

An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.
DNA Damage and Homologous Recombination
A01
A comparison of the mechanisms and cytotoxic activity of dianhydrogalactitol (VAL-083) to
cisplatin in ovarian tumor models harboring wild-type and mutant p53. Jeffrey A Bacha, Michelle
Martinez-Rivera, Guanghan He, Xiaolei Xie, Anne Steino, Sarath Kanekal, Dennis M Brown, Zahid H Siddik.
A02
CDK6 controls platinum sensitivity via the regulation of FOXO3a/ATR: A new actionable
pathway for ovarian cancer patients. Alessandra Dall’Acqua, Schiappacassi Monica, Gustavo Baldassarre.
A03
PARP inhibitor nanotherapy for ovarian cancer. Paige Baldwin, Anders Ohman, Jeremy Thong,
Shifalika Tangutoori, Daniela Dinulescu, Srinivas Sridhar.
A04
DNA double-strand break repair assay in primary cultures of patient-derived ovarian
carcinoma xenografts. Federica Guffanti, Julia Kaufmann, Francesca Bizzaro, Francesca Ricci, Monica
Ganzinelli, Monica Lupi, Raffaella Giavazzi, Lisa Wiesmüller, Giovanna Damia.
A05
BRCA1 promoter hypermethylation loss in recurrent high-grade serous carcinoma. Maria
Bisogna, Fanny Dao, Narciso Olvera, Ruben Bacares, Liying Zhang, Douglas A Levine.
A06, PR5
Identifying potential targets in Cyclin E-amplified tumors. Kai Doberstein, Alison Karst,
Dariush Etemadmoghadam , Paul Jones, Gavin Dunn, William Hahn, David Bowtell, Ronny Drapkin.
A07
Homologous recombination mutations and overall survival in high-grade serous,
endometrioid, and clear cell ovarian carcinomas. Maria I. Harrell, Matthew J. Maurer, Ethan P. Heinzen,
Ming K. Lee, Kimberly R. Kalli, Kathy J. Agnew, Ann L. Oberg, Tom Walsh, Barbara M. Norquist, Lynn C.
Hartmann, Scott H. Kaufmann, Elizabeth M. Swisher.
A08
Targeting the ATR/CHK1 axis in BRCA1/2 mutant ovarian cancer using an orthotopic patientderived xenograft (PDX) model. Hyoung Kim, Erin George, Eric Brown, Rugang Zhang, Clemens Krepler,
Janos Tanyi, Rachel Lee, Mark Morgan, Meenhard Herlyn, Fiona Simpkins.
A09
Targeting chemoresistant ovarian malignancies to cytostatic drugs and PARP inhibitors by
inhibition of CDK12 kinase activity. Jiri Kohoutek, Marek Svoboda, David Vrabel, Hana Paculova, Marta
Dzimkova.
A10, PR14
Exploiting synthetic lethality between the MK2 and p53 pathways with
nanotechnology to sensitize ovarian cancer to chemotherapy. Yi Wen Kong, Erik C Dreaden, Paula T
Hammond, Michael B Yaffe.
A11
NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the
PARP inhibitor rucaparib. Iain A McNeish, Kevin K Lin, James X Sun, Sandra Goble, Amit Oza, Robert L
Coleman, Clare L Scott, Gottfried Konecny, Anna V Tinker, David M O'Malley, Rebecca Kristeleit, Ling Ma,
James D Brenton, Katherine Bell-McGuinn, Ana Oaknin, Alexandra Leary, Elaina Mann, Heidi Giordano,
Roman Yelensky, Mitch Raponi, Elizabeth Swisher.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.
A12
Mutations in homologous recombination genes and response to treatment in GOG 218: An
NRG oncology study. Barbara M Norquist, Mark F Brady, Maria I Harrell, Tom D Walsh, Ming K Lee,
Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Robert A Burger, Susan A Davidson, Robert S Mannel,
Paul A DiSilvestro, Heather A Lankes, Nilsa C Ramirez, Mary Claire King, Michael J Birrer, Elizabeth M
Swisher.
A13
Transferrin facilitates the formation of DNA-double strand breaks via transferrin receptor 1 in
fallopian tube epithelial cells. Shogo Shigeta, Masafumi Toyoshima, Kazuyuki Kitatani, Masumi Ishibashi,
Toshinori Usui, Nobuo Yaegashi.
A14, PR02
Identification of germline and somatic alterations in homologous recombination
pathway genes in high grade ovarian carcinomas and response to the PARP inhibitor rucaparib in
ARIEL2. Elizabeth Swisher, Clare Scott, Kevin K Lin, Maria Harrell, James X Sun, Sandra Goble, Amit M Oza,
Robert L Coleman, Gottfried Konecny, Anna Tinker, David M O’Malley, Rebecca Kristeleit, Ling Ma, James
Brenton, Katherine Bell-McGuinn, Ana Oaknin, Alexandra Leary, Elaina Mann, Heidi Giordano, Roman
Yelensky, Mitch Raponi, Iain McNeish.
A15
The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer
cells to poly ADP ribose polymerase inhibitors via E2F1 downregulation. Andrew J Wilson, Jeanette
Saskowski, Dineo Khabele.
Molecular Drivers of Ovarian Cancer (other than p53)
A16
Regulation of TRAIL and NF-kappaB pathways in ovarian cancer. Mariam Anees, Umaima
Batool, Sidra Bukhari, Sohail Yousaf.
A17
The effects of atypical PKC inhibitors ICA-1 and ACPD on ovarian cancer cell proliferation,
RNA levels and atypical PKC levels. Christopher A Apostolatos, Minjel n/a Shah, Andre H Apostolatos.
A18
Targeting the Wnt-β-catenin pathway in primary ovarian cancer with the porcupine inhibitor
WNT974. Rebecca C Arend, Jonathan Boone, Sara J Cooper, Austin Gilchrest, Denise K Oelschlager, William
E Grizzle, William E Grizzle, Gerald McGwin, Abhishek Gangrade, Michael Straughn, Donald J Buchsbaum.
A19
Cytoplasmic ARID1A and poor outcome in ovarian cancer patients. Nicholas W Bateman, Kevin
A Byrd, Kelly A Conrads, Carl Morrison, Kunle Odunsi, Chad A Hamilton, G. Larry Maxwell, Thomas P
Conrads.
A20
Short-form Ron kinase as a novel therapeutic target in ovarian cancer. Magdalena Bieniasz,
Alana L Welm.
A21
Ovarian tumor cells' adhesion and cell signaling pathways are regulated by ARID3B. Alexander
S Bobbs, William Morgan Hallas, Karen D Cowden Dahl.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.
A22
Direct upregulation of STAT3 by miR551b in ovarian cancer. Pradeep Chaluvally-Raghavan,
Kang Jin Jeong, Sunila Pradeep, Yiling Lu, Anil Sood, Gordon Mills.
A23
The dual roles of microRNA-200: From inclusion cyst formation to cell migration. Pui Wah
Choi, Junzheng Yang, Wing Ping Fong, Ross S Berkowitz, William R Welch, Gregory J Goodall, Shu Wing Ng.
A24
Hypoxia signaling pathway plays a role in ovarian cancer chemoresistance. Noelle L Cutter,
Tyler Walther, Liam Gallagher, Robert Lucito, Kazimierz Wrzeszczynski.
A25
BRAFV600E mutations in serous ovarian cancer and response to the BRAF inhibitor,
dabrafenib. Anna DeFazio, Tania Moujaber, Dariush Etemadmoghadam, Catherine Kennedy, Yoke-Eng
Chiew, Rosemary L Balleine, Catherine Saunders, Gerard V Wain, Alexander Dobrovic, Australian Ovarian
Cancer Study Group (AOCS), David DL Bowtell, Paul R Harnett.
A26
Levels of phospho-Connexin 43 and phospho-TRKB in epithelial ovarian cancer. Maritza P
Garrido, Alberto Selman, Fernando Gabler, Margarita Vega, Carmen Romero.
A27
Transcriptome analyses of human ampulla and fimbriae highlight similarities and differences.
Sophia George, Anca Milea, Sowamber Ramlogan , Michael Considine, Leslie Cope, Noor Salman, Patricia
Shaw.
A28
Osteopontin splicing isoforms expression is modulated by partial epithelial mesenchymal
transition in ovarian carcinoma cells. Ingridy Celestino, Isabella S. Guimarães, Leticia B. A. Rangel, Etel R.
P. Gimba.
A29
YAP interacts with the ERBB signaling pathway to control ovarian surface epithelial cell
tumorigenesis. chunbo he, Xiangmin LV, John S Davis, Wang Cheng.
A30
Frizzled-7 (FZD7)-mediated non-canonical Wnt-Planar Cell Polarity (PCP) signaling pathway
as a novel molecular driver for the C5/Proliferative/Stem-A molecular subtype of ovarian cancer.
Mohammad Asad, Meng Kang Wong, Tuan Zea Tan, David Virshup, Jean Paul Thiery, Ruby Yun-Ju Huang.
A31
High-grade serous ovarian cancer subtyping identifies pathways for targeted therapy. Kaisa
Huhtinen, Ping Chen, Katja Kaipio, Piia Mikkonen, Viljami Aittomäki, Rony Lindell, Johanna Hynninen, Annika
Auranen, Seija Grenman, Rainer Lehtonen, Sampsa Hautaniemi, Olli Carpén.
A32
PBX1, a transcriptional regulator, promotes stemness and chemoresistance in ovarian cancer.
Jin-Gyoung Jung, Tae-Hoen Kim, Emily Gerry, Jen-Chun Kuan, Ayse Ayhan, Ben Davidson, Ie-Ming Shih,
Tian-Li Wang.
A33
Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly
sensitive and specific for small cell carcinoma of the ovary, hypercalcemic type. Anthony N Karnezis,
Yemin Wang, Pilar Ramos, William Hendricks, Holly Yin, Esther Oliva, Emanuela D’Angelo, Jaime Prat, Marisa
R Nucci, Torsten O Nielsen, Bernard E Weissman, Jeffrey M Trent, C Blake Gilks, David G Huntsman.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.
A34
Activation-induced cytidine deaminase links ovulation-induced inflammation and serous
carcinogenesis. Stav Sapoznik, Keren Bahar-Shany, Hadar Brand, Yishay Pinto, Orshay Gabay, Efrat GlickSaar, Chen Dor, Oranit Zadok, Iris Barshack, Adi Zundelevich, Einav Nili Gal-Yam , Yuval Yung, Ariel Hourvitz,
Jacob Korach, Mario Beiner, Jasmine Jacob, Erez Y Levanon, Michal Barak, Sarit Aviel-Ronen, Keren
Levanon.
A35
Elucidating mechanisms involved in long-term response to platinum-based chemotherapy in
high-grade serous ovarian cancer. Stephanie Lheureux, Cindy Yang, Patricia Shaw, Blaise Clarke, Julissa
Tsao, Katherine Karakasis, Marcus Butler, Noor Salman, Mark Dowar, Jing Xu, Laurent Poulain, Pamela S
Ohashi, Trevor Pugh, Amit Oza.
A36, PR18
Survival of ARHI-induced dormant autophagic cell death in vivo requires permissive
levels of VEGF, IL-8 and IGF-1 in the tumor microenvironment. Zhen Lu, Aaron F Orozco, Hailing Yang,
Margie N Sutton, Yan Wang, Weiqun Mao, Douglas A Levine, Robert C Bast, Robert C Bast.
A37
Yes-associated protein 1 (YAP) in the growth and tumorigenesis of ovarian granulosa cells.
Xiangmin Lv, Chunbo He, Guohua Hua, Jixin Dong, John S Davis, Cheng Wang.
A38
Identification through functional genomics screening of factors whose downregulation
enhances the side population in ovarian cancer. Noriomi Matsumura, Koji Yamanoi, Susan K Murphy,
Junzo Hamanishi, Kaoru Abiko, Ken Yamaguchi, Tsukasa Baba, Masafumi Koshiyama, Ikuo Konishi.
A39
FOXO1 is a key determinant of progesterone receptor isoform-specific senescence
programming in ovarian cancer cells. Caroline H Diep, Todd P Knutson, Laura J Mauro, Carol A Lange .
A40
Regulation of PAX2 in fallopian tube epithelium and high-grade serous ovarian carcinoma.
Dimple Ashok Modi, Rosemarie D Tagare, Joanna E Burdette.
A41
The heat shock transcription factor HSF1 induces ovarian cancer epithelial-mesenchymal
transition in a 3-D spheroid growth model. Trillitye Paullin, Chase Powell, Menzie Christopher, Robert Hill,
Christopher Martyniuk, Sandy Westerheide.
A42
TWIST1 as a driver of accelerated tumor growth and drug resistance: Potential novel pathways
and therapeutics. Cai M Roberts, Michelle A Tran, James Finlay, Sophia Allaf Shahin, Joana Loeza, Leslie
Cisneros, Emily Ye, Thanh Dellinger, Carlotta A Glackin.
A43
DIRAS1 and DIRAS2 are tumor suppressor candidates that inhibit cell growth, motility, and
proliferation while regulating autophagy in ovarian cancer. Margie N Sutton, Zhen Lu, Robert C Bast.
A44
Clinical value of immunohistochemical expression of EGFL7 within high-grade serous ovarian
cancer tissue. Jacek Jan Sznurkowski, Anton Zawrocki, Maciej Pawlowski.
A45
Proteins involved in the Calreticulin translocation pathway are altered in human ovarian
cancer samples. Carolina Vera, Paula García, Alberto Selman, Fernando Gabler, Margarita Vega, Arturo
Ferreira, Carmen Romero.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.
A46
Targeting transcriptional networks for ovarian cancer therapy. Sarah R Walker, Yixi Zhang,
Katarina Bartel, Yasmin Kroll, David A Frank.
A47
TGF-β inhibitors reduce ovarian cancer cells proliferation, migration, and invasion in vitro.
Qing Zhang, William A. Cliby.
Immunotherapy for Ovarian Cancer
A48
Ovarian tumor-induced immunosuppression of NK cells and its prevention by dietary
supplementation of herbal Withaferin A (Ashwagandha). Animesh Barua, Pincas Bitterman, Sameer
Sharma, Sanjib Basu, Janice M Bahr.
A49
Investigating the expression of inhibitory surface molecules in ovarian cancer tumorinfiltrating lymphocytes. Jessica Chacon, Tori Yamamoto, Thomas Garrabrant, Gabor Kari, Andrew Best,
Qunrui Ye, Daniel Powell.
A50
Chemoimmunotherapy with PD-1 blockade and paclitaxel induce a potent antitumor immunity
in ovarian cancers. Junzo Hamanishi, Jin Peng, Noriomi Matsumura, Kaoru Abiko, Tsukasa Baba, Ken
Yamaguchi, Ikuo Konishi, Masaki Mandai.
A51, PR03
Combinatorial blockade of PD-1, CTLA-4, and LAG-3 pathways inhibits murine ovarian
tumor growth. Ruea-Yea Huang, AJ McGray, Kunle Odunsi.
A52
Efficacy of specified natural killer (NK) cells in ovarian cancer xenograft models. Young Jae
Lee, Ha Young Lee, Yu Kyung Hwang, Kyung Jin Lee, Shin Wha Lee, Yong Man Kim.
A53
Combining oncolytic virotherapy with immunotherapy for ovarian cancer treatment. AJ Robert
McGray, Cheryl Eppolito, Kyle Stephenson, Jonathan Pol, Brian Lichty, Kunle Odunsi.
A54
Regulating MUC16 expression to decrease ovarian tumor proliferation and increase efficacy of
therapeutic antibodies. Mildred Felder, Arvinder Kapur, Ryan Serbin, San Zheng, May Xiong, Norishige
Yamada, Manish Patankar.
A55, PR04
Epigenetic treatment of ovarian cancer cells increases immune cell recruitment to the
tumor microenvironment: Implications for response to immune checkpoint therapy. Meredith Stone,
Katherine Chiappinelli, Huili Li, Lauren Murphy, Dimitris Mathios, Michael Lim, Stephen Baylin, Cynthia
Zahnow.
A56
Inhibition of Snail-induced EMT promotes anti-tumor immune response in ovarian cancer.
Mana Taki, Kaoru Abiko, Noriomi Matsumura, Tsukasa Baba, Junzo Hamanishi, Naoki Horikawa, Ikuo Konishi.
A57
Platinum induces IL-6-signaling mediated activation of ALDH1A1 and enriches the cancer stem
cell population in ovarian cancer. Yinu Wang, Anirban Kumar Mitra, Kenneth P Nephew.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.
A58
Bispecific anti-CD3-folate for the treatment of ovarian cancer. Jinming Xia, Kristine deDios,
Evelyn Rodrigo, Robin Humphreys, Alan Wahl, Marco Gymnopoulos.
A59
PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer. Shannon
Grabosch, Feitianzhi Zeng, Lixin Zhang, Mary Strange, Joan Brozick, Robert P Edwards, Anda Vlad.
Other
A60
DNA copy-number alterations in primary ovarian serous cystadenocarcinoma encoding for cell
transformation and predicting survival and response to platinum therapy throughout the course of the
disease. Orly Alter.
A61
Detection of ovarian cancer micrometastasis using nanoparticle-delivered probe targeted
towards tumor-associated neovasculature. Ayesha Alvero, Eydis Lima, Dongin Kim, Sean Orton, Mary
Pitruzzello, Yang Yang-Hartwich, Dan-Arin Silasi.
A62
TRX-1 targets chemoresistant tumor-initiating cells and prolongs survival in a recurrent
ovarian cancer animal model. Ayesha Alvero, Eydis Lima, Mary Pitruzzello, Yang Yang-Hartwich, David
Brown, Andrew Heaton, Gil Mor.
Prevention, Screening, Early Diagnostics, and Epidemiology
A63
The importance of cyclooxygenase 1 and 2 expression in ovarian cancer survival: Notable
differences by histologic subtype. Alicia Beeghly-Fadiel, Meral El Ramahi, Andrew Wilson, Spencer Keene,
Oluwole Fadare, Marta A. Crispens, Dineo Khabele.
Other
A64
β-catenin as a TIC therapeutic target in epithelial ovarian cancer. Anil Belur Nagaraj, Peronne
Joseph, Olga Kovalenko, Sareena Singh, Amy Armstrong, Analisa DiFeo.
A65
Nodal contributes to cisplatin resistance in ovarian cancer cells. Olena Bilyk.
Modeling Systems for Ovarian Cancer
A66
The CD73+/CD24- subpopulation of ovarian cancer cells is enriched in cancer stem cells.
Michela Lupia, Giovanni Bertalot, Pier Paolo Di Fiore, Nicoletta Colombo, Fabrizio Bianchi, Ugo Cavallaro.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.
Other
A67
Impact of estrogen on the response of ovarian tumor cells to cisplatin. Georgina Cheng, Carly
Galimanis , Heidi Baumgartner Wilson , Kian Behbakht.
A68
Sphingosine kinase 1 as a mediator and predictor of metformin’s protective effect in ovarian
cancer. Tatsuyuki Chiyoda, Xiaojing Liu, Ernst Lengyel, Jason Locasale, Iris Romero.
A69
The PAX8 cistrome in benign and malignant Mullerian epithelia. Kevin M Elias, Megan Emori,
Myles Brown, Ronny Drapkin.
A70
Epigenome and genome alterations in platinum resistant ovarian tumors. Fang Fang, Horacio
Cardenas, Dave Miller, Aaron Buechlein, Qing Yu, Yunlong Liu, Guanglong Jiang, Pietro Taverna, Harold Keer,
Doug Rusch, Daniela Matei, Kenneth P Nephew.
Ovarian Cancer Tumor Microenvironment
A71
The receptor tyrosine kinase, AXL, is a therapeutic target driving the mesenchymal phenotype
in ovarian cancer. Katherine C Fuh, Laura Divine, Michaela Soriano, Colleen Wu, Anh Diep, Andrew Loza,
Anne Gibson, Adam Krieg, Amato Giaccia, Erinn Rankin.
Other
A72
Dissecting the role of NF-kappaB signaling in ovarian cancer tumor-initiating cells. Carrie D
House, Christina M Annunziata.
A73
CDK4/6 inhibition as maintenance therapy in ovarian cancer. Mangala Iyengar, Lan Coffman,
Ronald Buckanovich.
A74
Proteasome subunit RPN13 as a candidate target for treatment of ovarian carcinoma. Rosie T
Jiang, Ravi K Anchoori, Anna V Yemelyanova, Chien-fu Hung.
A75
Big data and computational biology method for personalized prognosis of high grade serous
ovarian carcinoma. Ghim Siong Ow, Zhiqun Tang, Anna Vladimirovna Ivshina, Vladimir Andreevich
Kuznetsov.
A76
Targeting phosphodiesterase 10A for chemoprevention and treatment of ovarian cancer.
Luciana Madeira da Silva, Elaine Gavin, Kevin Lee, Ileana Aragon, Veronica Ramírez-Alcántara, Jennifer
Scalici, Rodney P Rocconi, Gary A Piazza.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.
A77
Validation of the EORTC QLQ-OV28 instrument for the assessment of quality of life in women
with ovarian carcinoma in Mexico. Dolores Gallardo-Rincon, Wendy Munoz-Montano, David Cantu de
Leon, Jaime Coronel-Martinez, Flavia Morales, Luis F Onate-Ocana.
Ovarian Cancer Tumor Microenvironment
A78
Serum metabolomics, cytokine measurements, and tumor RNA-seq identified phospholipids
correlated with a molecular subclass as strong predictor for outcome in high grade serous ovarian
cancer. Stefanie Aust, Anna Bachmayr-Heyda, Katharina Auer, Nyamdelger Sukhbaatar, Samuel M. Meier,
Christopher Gerner, Dietmar Pils.
Other
A79
Thioxodihydroquinazolinone small molecules that sensitize ovarian cancer stem cells to
platinum therapy. Wei Qian, Jing Ma, Peter Wipf, Bennett Van Houten.
A80
NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1
transcription in ovarian cancer (OVCA). Alice Laschuk Herlinger, Min Gao, Ren-Chin Wu, Tian-Li Wang,
Leticia B A Rangel, Ie-Ming Shih.
A81
Targeting of free fatty acid signaling in ovarian cancer may serve as a potential therapeutic
approach. Adnan Munkarah, Suhail Hamid, Jasdeep Chhina, Ismail Mert, LaToya Jackson, Sharon HensleyAlford, Dhananjay Chitale, Shailendra Giri, Ramandeep Rattan .
A82
Ovarian cancer cells hijack immune functions of omental milky spots for metastatic
colonization. Venkatesh Krishnan, Kelly Mitchell, Jason Miska, Sophia George, Patricia Shaw, Victoria
Seewaldt, Maciej Lesniak, Marina Chekmareva, Lev Becker, Vinita Parkash, Cindy Miranti, Carrie RinkerSchaeffer.
A83
Profiling potent, novel protein tyrosine phosphatase 4A3 small molecule inhibitors for ovarian
cancer. Elizabeth R. Sharlow, Joseph M. Salamoun, Kelley E. McQueeney, Sophie Lewandowski, Jennifer
Bryant, Alex Cheung, Paula Pekic, Charles N. Landen, Peter Wipf, John S. Lazo.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.
Molecular Drivers of Ovarian Cancer: p53
B01
Mutagenic and tumorigenic effects of follicular fluid in the context of p53 loss: Initiation of
fimbria carcinogenesis. Tang-Yuan Chu, Hsuan-Shun Huang, Che-Fang Hsu.
B02
Oxidized hemoglobin promotes survival of ROS-stressed and DNA damaged fallopian tube
epithelial cells with p53 loss, resulting in a copy number variation phenotype of HGSC. Hsuan-Shun
Huang, Che-Fang Hsu, Tang-Yuan Chu.
B03, PR12
Mutant p53 drives early events in fallopian tube tumorigenesis through mesenchymeassociated autocrine production of matrix that supports survival and mesothelial intercalation. Marcin
P Iwanicki, Hsing-Yu Chen, Ioannis Zervantonakis, Marian Novak, Taru Muranen, Tan A Ince , Ronny Drapkin ,
Joan S Brugge.
B04
Early detection of ovarian cancer recurrence using p53-mutated circulating tumor DNA as
non-invasive biomarkers. Ha-Young Lee, Shin-Wha Lee, Geum-Hee Na, Sang-Eun Lee, Dong-Woo Kang,
Yong-Man Kim.
B05
Assessment of TP53 mutation status in primary high-grade serous ovarian cancer and cell line
models: Comparison between immunohistochemistry and next generation sequencing. Alexander J
Cole, Trisha Dwight, Ying Zhu, Anthony J Gill, Kristie-Ann Dickson, Adele Clarkson, Gregory B Gard, Jayne
Maidens, Susan Valmadre, Roderick J Clifton-Bligh, Deborah J Marsh.
B06, PR13
A designed inhibitor of p53 self-aggregation rescues p53 tumor-suppression function
in high-grade serous ovarian carcinoma. Alice Soragni, Deanna M Janzen, Lisa Johnson, Anne G Lindgren,
Anh TQ Nguyen, Ekaterina Tiourin, Angela B Soriaga, Jing Lu, Lin Jiang, Kym F Faull, Matteo Pellegrini,
Sanaz Memarzadeh, David S Eisenberg.
Non-Serous Ovarian Cancer
B07, PR7
Synchronous ovarian and endometrial carcinomas: The case for pseudo-metastasis.
Michael S Anglesio, Yi Kan Wang, Madlen Maassen, Hugo M Horlings, Ali Bashashati, Blake Gilks, Stefan
Kommoss, David G Huntsman.
B08
Genomics analyses of less common epithelial ovarian cancer subtypes. Kylie L Gorringe,
Matthew Wakefield, Sally M Hunter, Georgina L Ryland, Dane Cheasley, Michael S Anglesio, Michael Christie,
Raghwa Sharma, Antill Yoland, Simone M Rowley, Jason Li, Blake Gilks, Prue E Allan, Andrew N Stephens,
Sumi Ananda, Jan Pyman, Martin Koebel, Jessica McAlpine, Charlie Gourley, David G Huntsman, Anna
deFazio, David DL Bowtell, Ian G Campbell, Clare Scott.
B09
Roles of iASPP, PLK1 and autophagy in ovarian clear cell carcinoma. Ka Kui Chan, Gee Wan
Oscar Wong, Kar Loen Karen Chan , Nga Yin Annie Cheung.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.
B10
FOXL2 402C>G mutation can be identified in the circulating tumor DNA of patients with
adult-type granulosa cell tumor. Anniina Färkkilä, Melissa K McConechy, Winnie Yang, Aline Talhouk, Ying
Ng, Ryan Morin, Annika Riska, Jessica N McAlpine, Leila Unkila-Kallio, Mikko Anttonen, David G Huntsman.
B11
Mutational heterogeneity in non-serous ovarian cancers. Jaime Teer, Sean Yoder, Anxhela
Gjyshi, Chaomei Zhang, Alvaro Monteiro.
B12
Targeted sequencing of ovarian clear cell carcinomas reveals intertumor heterogeneity and
distinct clustering related to mutational load. Jenny-Maria Jönsson, Nicolai Skovbjerg Arildsen, Anna
Ebbesson, Sofia Westbom-Fremer, Anna Måsbäck, Susanne Malander, Mef Nilbert, Ingrid Hedenfalk.
B13
Discovery of novel subtype-specific ovarian cancer biomarkers via integrated tissue
proteomics. Felix Leung, Marcus Q Bernardini, Blaise Clarke, Marjan Rouzbahman, Eleftherios P Diamandis,
Vathany Kulasingam.
B14
Molecular characterization of mucinous ovarian carcinoma. Brooke Schlappe, Jennifer J Mueller,
Narciso Olvera, Fanny Dao, Cyriac Kandoth, Faina Bogomolniy, Agnes Viale, Kety Huberman, Gouri
Nanjangud, Yaser Hussein, Barry Taylor, Robert Soslow, Douglas A Levine.
B15
Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary,
hypercalcemic type. Jill H Tseng, Petar Jelinic, Brooke A Schlappe, Niamh Conlon, Narciso Olvera, Fanny
Dao, Jennifer J Mueller, Yaser Hussein, Robert A Soslow, Douglas A Levine.
B16
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated ovarian
cancers. Benjamin Bitler, Ie-Ming Shih, Rugang Zhang.
Prevention, Screening, Early Diagnostics, and Epidemiology
B17
Type 2 diabetes, metformin, and ovarian cancer survival: An analysis of tumor registry and
electronic medical record data. Spencer Keene, Samantha P. Stansel, Leshaun Clayton, Min Jiang, Melinda
Aldrich, Hua Xu, Jeremy Warner, Joshua Denny, Dineo Khabele, Alicia Beeghly-Fadiel.
B18
Prediagnostic physical inactivity and epithelial ovarian cancer risk and mortality: Evidence
from the Ovarian Cancer Association Consortium. Rikki A Cannioto, Michael LaMonte, Ovarian Cancer
Association Consortium (OCAC), Kirsten B Moysich.
B19, PR16
Computational modeling of serous ovarian carcinoma dynamics: Implications for
screening and therapy. Shengqing Gu, Stephanie Lheureux, Azin Sayad, Liat Hogen Ben-David, Iryna
Vyarvelska, Paulina Cybulska, Marcus Bernardini, Barry Rosen, Amit Oza, Benjamin G Neel.
B20
Uptake and safety of bilateral salpingectomy for ovarian cancer prevention in the United
States. Gillian Hanley, Jessica McAlpine, Leigh Pearce.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.
B21
BRCA mutation status is not associated with better long-term survival from epithelial ovarian
cancer. Joanne Kotsopoulos, Isabel Fan, John McLaughlin, Barry Rosen, Taymaa May, Harvey Risch, Ping
Sun, Steven Narod.
B22
Exploring the effects of incomplete pregnancies on risk of ovarian cancer. Alice W Lee, Celeste
Leigh Pearce, Malcolm C Pike, Anna H Wu.
B23, PR10
Detection of Müllerian duct carcinomas by lavage of the uterine cavity and mutation
analysis – A new concept. Elisabeth Maritschnegg, Yuxuan Wang, Nina Pecha, Reinhard Horvat, Els Van
Nieuwenhuysen, Ignace Vergote, Jalid Sehouli, Isaac Kinde, Luis A Diaz, Nickolas Papadopoulos, Kenneth W
Kinzler, Bert Vogelstein, Robert Zeillinger, Paul Speiser.
B24
Personal history of endometriosis and survival in ovarian cancer patients: A pooled analysis of
10 studies from the Ovarian Cancer Association Consortium. Albina N Minlikeeva, Jo L Freudenheim, C.
Leigh Pearce, J.Brian Szender, Ovarian Cancer Association Consortium, Kirsten B Moysich.
B25
Preclinical evaluation of radiolabeled MUC16 antibodies for PET imaging of epithelial ovarian
carcinoma. Brandon E Nemieboka, Dharmarao Thapi, Ariana Bitton, Jason S Lewis.
B26
Cell surface expression of CD44v8-10 is associated with good prognosis while cleaved
extracellular domain is a marker of poor prognosis in high-grade serous epithelial ovarian cancer.
David Pepin, Amanda Sosulski, Heiko Horn, Lihua Zhang, Caroline Coletti, vinod Vathipadiekal, Cesar M
Castro, Michael J Birrer, Osamu Nagano, Hidekuyi Saya, Kasper Lage, Patricia K Donahoe.
B27
Investigation of small GTPase genes in epithelial ovarian cancer. Hui-Yi Lin, Yin Xiong, Jonathan
Tyrer, Douglas C Marchion, Alvaro NA Monteiro, Andrew Berchuck, Joellen M Schildkraut, Ellen L Goode,
Susan J Ramus, Simon A Gayther, Paul DP Pharoah, Steven A Narod, Thomas A Sellers, Catherine M Phelan.
B28
Validation of a combined 13 gene six protein blood signature for earlier detection of ovarian
cancer. Anna Bachmayr-Heyda, Stefanie Aust, Katharina Auer, Peter Borossay, Nina Pecha, Ugo Cavallaro,
Ioana Braicu, Sarah Igidbashian, Costanza Savino, Franchi Dorella, Jalid Sehouli, Sonia Zaafrani, Florian
Fitzal, Christian Singer, Michael Gnant, Robert Zeillinger, Dietmar Pils.
B29
Pre- and post-diagnosis analgesic use and ovarian cancer survival. Elizabeth M Poole, Megan S
Rice, Shelley S Tworoger.
B30
Dietary fat intake and ovarian cancer risk. Megan Rice, Shelley Tworoger.
B31
Circulating periostin as a potential biomarker to predict platinum-resistant epithelial ovarian
cancer. Lisa Ryner, Amy Noyes, Denise Nazzal, Paul Vu, Yinghui Guan, Shan Lu, Alyssa Morimoto, Sue
Brignoli, Yulei Wang.
B32
Serum calcium and serum albumin can discriminate malignant from benign pelvic masses.
Gary G Schwartz, Michael G Kelly, Stuart S Winkler, Samuel S Lentz, Steve H Berliner , Melissa F Swain,
Halcyon G Skinner.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.
B33
Reproductive and hormonal risk factors in relation to ovarian cancer survival and platinum
resistance. Amy L Shafrir, Ana Babic, Rulla M Tamimi, Bernard A Rosner, Shelley S Tworoger, Kathryn L
Terry.
B34
Tandem Mass Tag 10-plex isobaric labeling of Pap test proteins: A novel method for the
identification of ovarian cancer protein biomarkers by mass spectrometry. Amy P.N. Skubitz, Somi
Afiuni, Kristin L.M. Boylan, Melissa Geller, Peter Argenta, Samantha Hoffman, Timothy Griffin.
B35
Ovarian cancer incidence projections in the United States: Expected increases through 2030.
Sherri L Stewart, Trevor D Thompson, Hannah K Weir, Sun Hee Rim.
B36
In vivo laser-based imaging of the human fallopian tube for future cancer detection. Elizabeth
M. Swisher, C. David Melville, Richard S Johnston, Kathy Agnew, Seine Chiang, Eric J Seibel.
B37
Menstrual cycle characteristics, PCOS, and ovarian cancer risk. Holly R Harris, Linda J Titus,
Daniel W Cramer, Kathryn L Terry.
B38, PR11
Prediagnosis adiposity, physical activity, and ovarian cancer survival. Adetunji T
Toriola, Kathleen Keogan, Leavitt Morrison, Lisa Pollack, Sara Gerhlert, Yikyung Park, Louise Brinton.
B39
Serum estrogen and estrogen metabolites and risk of ovarian cancer among postmenopausal
women in the Women’s Health Initiative Observational Study. Britton Trabert, Garnet L. Anderson,
Louise A. Brinton, Roni T. Falk, Barbara J. Fuhrman, Margery L. Gass, Lewis H. Kuller, Ruth Pfeiffer, Sarunas
Sliesoraitis, Howard D. Strickler, Xia Xu, Nicolas Wentzensen.
B40
Pre-diagnosis leukocyte telomere length and risk of ovarian cancer. Meng Yang, Jennifer
Prescott, Elizabeth M Poole, Megan S Rice, Annika Idahl, Eva Lundin, Immaculata De Vivo , Shelley S
Tworoger.
B41
Methylation profiling of ovarian cancer to study etiologic and prognostic heterogeneity and to
develop a molecular classifier. Clara Bodelon, Keith Killian, Joshua Sampson, Holly Stevenson, William
Anderson, Rayna Matsuno, Louise Brinton, Jolanta Lissowska, Mark Sherman, Nicolas Wentzensen.
B42
Identification of nucleic acid aptamers for ovarian cancer biomarkers using multiple selection
modes and high-throughput sequencing. Rebecca J Whelan, Arvinder Kapur, Mildred Felder, Jamie
Shallcross, Manish S Patankar.
Modeling Systems for Ovarian Cancer
B43
Characterization of ovarian cancer cells as in vivo models for preclinical studies. Lidia
Hernandez, Marianne K Kim, L Tiffany Lyle, Patricia S Steeg, Christina M Annunziata.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.
B44, PR08
Evidence for extra-ovarian origin and peritoneal metastases that precede ovarian
carcinomas in high-grade serous ovarian cancer. Jeremy Chien, Viji Shridhar, Andrea Mariani.
B45
Chu.
Characterization of human fallopian tube epithelial stem-like cells. Dah-Ching Ding, Tang-Yuan
B46
Use of a novel orthotopic ovarian cancer transplant patient derived xenograft model as a
preclinical platform for bench to bedside research. Erin George, Hyoung Kim, Clemens Krepler, Janos
Tanyi, Zhi Wei, Katrin Sproesser, Patricia Brafford, Marilda Beqiri, Adina-Monica Vultur, Rachel Lee, Mark
Morgan, Ronny Drapkin, Tan Ince, Meenhard Herlyn, Fiona Simpkins.
B47
Novel integrative approach to identify therapy sensitive and insensitive ovarian cancer
patients. Ping Chen, Kaisa Huhtinen, Katja Kaipio, Piia Mikkonen, Viljami Aittomaki, Rony Lindell, Johanna
Hynninen, Annika Auranen, Seija Grenman, Rainer Lehtonen, Olli Carpén, Sampsa Hautaniemi.
B48
Design of effective combination therapies for high-grade serous ovarian cancer using patientderived xenograft models. Claudia Iavarone, Ioannis Zervantonakis, Hsing-Yu Chen, Sangeetha S
Palakurthi, Joyce Fu Liu, Ursula A Matulonis, Ronny I Drapkin, Gordon B Mills, Joel D Leverson, Deepak
Sampath, Joan S Brugge.
B49
Giant cancer stem cells of high grade ovarian serous carcinoma. Jinsong Liu.
B50
Anti-neoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor
rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models.
Caroline C Nitschmann, Rachel M Hurley, Marc A Becker, Xiaonan Hou, Ute Hoch, Thomas C Harding,
Deborah H Charych, Scott H Kaufmann, Paul Haluska, Saravut J Weroha .
B51
Stress management: LKB1 controls growth and survival of dormant epithelial ovarian cancer
spheroid cells. Trevor G Shepherd, Yudith Ramos Valdes, Teresa Peart, Meera Shah, Gabriel E DiMattia.
B52
The epithelial-mesenchymal transition factor Snail represses the tumor suppressor microRNA
let-7 and contributes to invasiveness of ovarian cancer cells. Yevgeniya Ioffe, Alyse Hill, Michael
McCarthy, Linda Sanderman, Hugo Campos, Tise Suzuki, Andrew Caster, Juli Unternaehrer-Hamm.
B53
CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of
high grade serous ovarian cancer. Josephine Walton, Suzanne Dowson, Darren Ennis, Elaine Leung,
Malcolm Farquharson, David Stevenson, Karen Blyth, Douglas Strathdee, Frances R Balkwill, Michelle
Lockley, Iain A McNeish.
Ovarian Cancer Tumor Microenvironment
B54
Single and collective cell dissemination modes in ovarian cancer. Sara Al-Habyan, Joseph
Szymborski, Patricia Tonin, Luke McCaffrey.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.
B55
Peritoneal tumor spread in high grade serous ovarian cancer: Differences in the immune
response. Katharina Auer, Anna Bachmayr-Heyda, Nyamdelger Sukhbaatar, Stefanie Aust, Christoph
Grimm, Reinhard Horvat, Dietmar Pils.
B56
Peritoneal tumor spread in high grade serous ovarian cancer: An effect of the competing
endogenous RNA network? Anna Bachmayr-Heyda, Katharina Auer, Nyamdelger Sukhbaatar, Stefanie
Aust, Simon Deycmar, Agnes T. Reiner, Stephan Polterauer, Sabine Dekan, Dietmar Pils.
B57
Sucrose nonfermenting 1-related kinase (SNRK) expression and function in ovarian cancer.
Erin A Bishop, Stephanie M Cossette, Ramani Ramchandran.
B58
Functional analysis of the cell adhesion molecule Nectin-4 in the unique tumor
microenvironment of ovarian cancer. Kristin L.M. Boylan, Petra C. Buchanan, Dip Shukla, Melissa DeRycke,
Bruce Walcheck, Amy P.N. Skubitz.
B59
The adhesion molecule L1: A new driver in ovarian cancer vasculature. Francesca Angiolini,
Elena Magrini, Pier Paolo Di Fiore, Ugo Cavallaro.
B60
Identification of an ovarian tumor:stromal HH:BMP4 signaling loop critical to ovarian cancer
growth and chemotherapy resistance. Lan G Coffman, Yunjung Choi, Karen Mclean, Marina Pasca di
Magliano, Benjamin Allen, Ronald J Buckanovich.
B61
Leptin induces a pro-inflammatory macrophage-cancer cell reinforcement loop that favors
high-grade serous ovarian cancer progression among overweight/obese women. Mauricio A Cuello,
Lorena Abarzua-Catalan, Sumie Kato, Isidora Solar, Claudia Arancibia.
B62
Discoidin domain receptor 2 (DDR2) modulates invasion and metastasis via epithelial
mesenchymal transition in ovarian cancer. Laura Divine, Whitney Grither, Eric Meller, Anne Gibson,
Andrew Loza, Riva Desai, Gregory Longmore, Katherine Fuh.
B63
Expression of VEGF in ovarian cancer suppresses tumor immunity through recruitment of
myeloid derived suppressor cells. Naoki Horikawa, Kaoru Abiko, Noriomi Matsumura , Junzo Hamanishi,
Susan Murphy, Tsukasa Baba, Ken Yamaguchi, Masafumi Koshiyama, Ikuo Konishi.
B64
Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways
characteristic of increased stromal activation. Zhenqiu Liu, Jessica A Beach, Hasmik Agadjanian, Dongyu
Jia, Paul-Joseph Aspuria, Beth Y Karlan, Sandra Orsulic.
B65, PR17
Characterization of ascites and tumor derived ovarian cancer stem-like cells. Katja
Kaipio, Ping Chen, Kaisa Huhtinen, Piia Mikkonen, Paivi Ostling, John Patrick Mpindi, Laura Lehtinen, Pia
Roering, Taina Korpela, Krister Wennerberg, Bhagwan Yadav, Tero Aittokallio, Evgeny Kulesskiy, Johanna
Hynninen, Annika Auranen, Seija Grénman, Sampsa Hautaniemi, Olli Carpén.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.
B66
Blockade of PD-1 signaling in tumor-associated dendritic cells results in compensatory IL-10
release maintaining immune suppression in ovarian cancer microenvironments. Purushottam
Lamichhane, Lavakumar Karyampudi, Barath Shreeder, James Krempski, Deborah Bahr, Matthew Block,
Keith Knutson.
B67
The impact of parity on the metastatic success of ovarian cancer. Elizabeth A Loughran, Ryan
Phan, Annemarie K Leonard , Laura Tarwater, Marwa Asem, Yuliya Klymenko, Yueying Liu, Jing Yang, Jeff
Johnson, Matthew Ravosa, M. Sharon Stack.
B68
Erythropoietin stimulates ovarian tumor growth via EphB4. Sunila Pradeep, Jie Huang, Edna
Mora, Sherry Y Wu, Chun Li, Gabriel Lopez-Berestein, David Jackson, Anil Sood.
B69
Notch3 signal activation promotes peritoneal metastasis in a mouse model of epithelial
ovarian cancer. Jessica Price, Elham Azizi, Nathaniel Jones, Jan Kitajewski.
B70
Targeted activation of macrophages to limit ovarian cancer progression. Whitney Barham,
Andrew Wilson, Ryan Ortega, Jeanette Saskowski, Oleg Tikhomirov, Todd Giorgio, Dineo Khabele, Fiona E
Yull.
Other
B71
Old age and chemotherapy contribute to the selection of PPM1D somatic mosaic mutations in
ovarian cancer. Maria I. Harrell, Barbara M. Norquist, Tom Walsh, Mark F. Brady, Ming K. Lee, Robert
Hershberg, Kimberly R. Kalli, Heather Lankes, Eric Q. Konnick, Colin C. Pritchard, Bradley J. Monk, John K.
Chan, Robert Burger, Scott H. Kaufmann, Michael J. Birrer, Elizabeth M. Swisher.
Immunotherapy for Ovarian Cancer
B72
Long-term survival and outcome update on patients (pts) with recurrent ovarian cancer who
received ipilimumab post GVAX vaccine. Ursula Anne Matulonis, Stephen Hodi , Glenn Dranoff , Susana
Campos, Richard Penson, Robert Soiffer, Marcus Butler.
Other
B73
The monoterpene, citral, increases intracellular oxygen radicals and inhibits cancer cell
proliferation by inducing apoptosis and endoplasmic reticulum stress. Arvinder Kapur, Mildred Felder,
Lucas Fass, Justanjyot kaur, Austin Czarnecki, Kavya Rathi, Manish Patankar.
An AACR Special Conference on
Advances in Ovarian Cancer Research:
Exploiting Vulnerabilities
October 17-20, 2015 • Hyatt Regency • Orlando, FL
Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.
B74
Can we repurpose anti-malarial drug quinacrine to treat ovarian cancer? Debarshi Roy,
Ashwani Khurana, Eleftheria Kalogera, Xuyang Wen, Susmita Mondal, Viji Shridhar.
B75
Increased basal autophagy decreases sensitivity to cisplatin in chemoresistant ovarian cancer.
Thomas R. Silvers, Peter R. Dottino, John A. Martignetti, Brad R. Evans.
B76
Involuntary weight loss is an independent prognostic factor for overall survival and predicts
better response to chemotherapy in high-grade serous ovarian cancer patients. j Jan Sznurkowski,
Maciej Pawlowski, Pawel Kabata.
B77
Examining selection for resistant clones in high-grade serous ovarian cancer after neoadjuvant
chemotherapy. Alicia Tone, Jocelyn Stewart, Carl Virtanen, Marcus Bernardini, Stephane Laframboise,
Sarah Ferguson, Amit Oza, Theodore Brown, Taymaa May.
B78
Differential methylation of HIST1H2BB and MAGI2 in ovarian cancers. Blanca L Valle, Elisabetta
Kuhn, David Sidransky, Rafael Guerrero-Preston.
B79
Translational study of tumor treating fields in combination with paclitaxel in ovarian cancer.
Mijal Munster, Roni Blat, Paul C Roberts, Eva M Schmelz, Moshe Giladi, Rosa S Schneiderman, Yaara Porat,
Zeev Bomzon, Noa Urman, Aviran Itzhaki, Tali Voloshin, Shay Cahal, Eilon D Kirson, Uri Weinberg, Yoram
Palti .
B80
Tumor expression subtypes of high-grade serous ovarian cancer demonstrate associations
with likelihood of complete resection: a single-center study. Chen Wang, Jamie Bakkum-Gamez, Andrea
Mariani, William Cliby, Ellen Goode.
Molecular Drivers of Ovarian Cancer (other than p53)
B81
The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer
cells to the cyclin-dependent kinase 2 inhibitor dinaciclib. Andrew J Wilson, Jeanette Saskowski, Dineo
Khabele.
Other
B82
Application of modulated electro-hyperthermia for the cellular target therapy in ovarian
cancer cells. Wookyeom Yang, Doo Byung Chay, Hanbyoul Cho, Sunghoon Kim, Jinkyoung Kong,
Geumseon Son, Jihui Choi, Kim Jae-hoon.